📊 RNXT Key Takeaways
Is RenovoRx, Inc. (RNXT) a Good Investment?
RenovoRx is a pre-commercial pharmaceutical company with impressive 85% gross margins but catastrophic operating losses of $3.5M against only $563K in revenue. Despite no debt and a reasonable cash position, the company is burning $3.7M in operating cash flow quarterly with ~3-4 quarters of runway remaining, making near-term viability dependent on achieving critical operational milestones.
Revenue has inflected from a very low base with strong gross margins, but operations remain deeply unprofitable with extreme negative operating and net margins. Cash burn materially exceeds scale of the business, implying likely near-term financing needs; without clear operating leverage and sustained revenue traction, fundamentals are unfavorable.
Why Buy RenovoRx, Inc. Stock? RNXT Key Strengths
- Exceptional gross margin of 85.1% demonstrates core product economics are sound
- Strong balance sheet with zero significant debt, $11.3M stockholders equity, and $12.4M cash position
- Explosive revenue growth of +2511.6% YoY indicates emerging market traction despite small absolute base
- High gross margin (70.9%) indicating potential unit economics if scaled
- Solid liquidity (current ratio 4.0x) with zero long-term debt
- Minimal capex supports an asset-light model
RNXT Stock Risks: RenovoRx, Inc. Investment Risks
- Operating losses of $3.5M dwarf revenue of $563K, indicating company is not near profitability
- Negative operating cash flow of $3.7M per period with estimated 3-4 quarters of cash runway at current burn rate
- Pre-commercial pharma stage with extreme execution risk; success depends on regulatory approval and market adoption
- Severe operating losses and negative ROE/ROA point to unsustainable economics
- High cash burn relative to $7.02M cash raises financing/dilution risk
- Execution/regulatory uncertainty typical in pharma could hinder commercialization
Key Metrics to Watch
- Quarterly revenue growth sustainability and gross margin maintenance as commercialization scales
- Operating cash burn trajectory and cash runway extension through financing or profitability
- Regulatory approval status and clinical development pipeline advancement
- Operating cash flow (quarterly burn rate)
- Operating margin (progress toward breakeven)
RenovoRx, Inc. (RNXT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.15x current ratio provides a solid financial cushion.
RNXT Profit Margin, ROE & Profitability Analysis
RNXT vs Healthcare Sector: How RenovoRx, Inc. Compares
How RenovoRx, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RenovoRx, Inc. Stock Overvalued? RNXT Valuation Analysis 2026
Based on fundamental analysis, RenovoRx, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RenovoRx, Inc. Balance Sheet: RNXT Debt, Cash & Liquidity
RNXT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: RenovoRx, Inc.'s revenue has grown significantly by 2,512% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.40 indicates the company is currently unprofitable.
RNXT Revenue Growth, EPS Growth & YoY Performance
RNXT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $197.0K | -$2.4M | $-0.08 |
| Q3 2025 | $266.0K | -$1.1M | $-0.08 |
| Q2 2025 | $422.0K | -$1.1M | $-0.08 |
| Q1 2025 | $197.0K | -$1.1M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RenovoRx, Inc. Dividends, Buybacks & Capital Allocation
RNXT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for RenovoRx, Inc. (CIK: 0001574094)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RNXT
What is the AI rating for RNXT?
RenovoRx, Inc. (RNXT) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RNXT's key strengths?
Claude: Exceptional gross margin of 85.1% demonstrates core product economics are sound. Strong balance sheet with zero significant debt, $11.3M stockholders equity, and $12.4M cash position. ChatGPT: High gross margin (70.9%) indicating potential unit economics if scaled. Solid liquidity (current ratio 4.0x) with zero long-term debt.
What are the risks of investing in RNXT?
Claude: Operating losses of $3.5M dwarf revenue of $563K, indicating company is not near profitability. Negative operating cash flow of $3.7M per period with estimated 3-4 quarters of cash runway at current burn rate. ChatGPT: Severe operating losses and negative ROE/ROA point to unsustainable economics. High cash burn relative to $7.02M cash raises financing/dilution risk.
What is RNXT's revenue and growth?
RenovoRx, Inc. reported revenue of $563.0K.
Does RNXT pay dividends?
RenovoRx, Inc. does not currently pay dividends.
Where can I find RNXT SEC filings?
Official SEC filings for RenovoRx, Inc. (CIK: 0001574094) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RNXT's EPS?
RenovoRx, Inc. has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RNXT a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, RenovoRx, Inc. has a SELL rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RNXT stock overvalued or undervalued?
Valuation metrics for RNXT: ROE of -31.3% (sector avg: 15%), net margin of -625.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RNXT stock in 2026?
Our dual AI analysis gives RenovoRx, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RNXT's free cash flow?
RenovoRx, Inc.'s operating cash flow is $-3.7M, with capital expenditures of $0.0. FCF margin is -658.8%.
How does RNXT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -625.4% (avg: 12%), ROE -31.3% (avg: 15%), current ratio 7.15 (avg: 2).